Tipranavir optimizes the effect of recent antiretroviral substances. Encouraging options in multiple resistance
MMW Fortschritte der Medizin 150 Spec No 1: 71
2008
ISSN/ISBN: 1438-3276 PMID: 19024922 Document Number: 622163
Document emailed within 1 workday
Related Documents
Vergne, L.; Malonga-Mouellet, G.; Mistoul, I.; Mavoungou, R.; Mansaray, H.; Peeters, M.; Delaporte, E. 2002: Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries Journal of Acquired Immune Deficiency Syndromes 29(2): 165-168Vergne, L.; Malonga-Mouellet, G.; Mistoul, I.; Mavoungou, R.; Mansaray, H.; Peeters, M.; Delaporte, E. 2002: Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries Journal of Acquired Immune Deficiency Syndromes 29(2): 165-168
Hamers, R.L.; Schuurman, R.; Sigaloff, K.C.E.; Wallis, C.L.; Kityo, C.; Siwale, M.; Mandaliya, K.; Ive, P.; Botes, M.E.; Wellington, M.; Osibogun, A.; Wit, F.W.; van Vugt, M.èl.; Stevens, W.S.; de Wit, T.F.R. 2012: Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study LANCET. Infectious Diseases 12(4): 307-317
Motohashi, N.; Kurihara, T.; Kawase, M.; Hevér, A.; Tanaka, M.; Szabo, D.; Nacsa, J.; Yamanaka, W.; Kerim, A.; Molnár, J. 1997: Drug resistance reversal, anti-mutagenicity and antiretroviral effect of phthalimido- and chloroethyl-phenothiazines Anticancer Research 17(5a): 3537-3543
Baesi, K.; Ravanshad, M.; Ghanbarisafari, M.; Saberfar, E.; Seyedalinaghi, S.; Volk, J.E. 2014: Antiretroviral drug resistance among antiretroviral-naïve and treatment experienced patients infected with HIV in Iran Journal of Medical Virology 86(7): 1093-1098
Corzillius, M.; Mühlberger, N.; Sroczynski, G.; Jaeger, H.; Wasem, J.ür.; Siebert, U. 2004: Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV Antiviral Therapy 9(1): 27-36
Hellwig, B. 2015: New active substances expand the treatment options for MS Medizinische Monatsschrift für Pharmazeuten 38(2): 65-68
Hamers, R.L.; Wallis, C.L.; Kityo, C.; Siwale, M.; Mandaliya, K.; Conradie, F.; Botes, M.E.; Wellington, M.; Osibogun, A.; Sigaloff, K.C.E.; Nankya, I.; Schuurman, R.; Wit, F.W.; Stevens, W.S.; van Vugt, Mèle.; de Wit, T.F.Rinke.; Mandaliya, K.; Abdallah, S.; Jao, I.; Dolan, M.; Schuurman, R.; Wensing, A.M.; Hamers, R.L.; Sigaloff, K.C.E.; Straatsma, E.; Wit, F.W.; van Vugt, M.; Lange, J.M.; Rinke de Wit, T.F.; Osibogun, A.; Akanmu, S.; Botes, M.E.; Conradie, F.; Ive, P.; Sanne, I.; Wallis, C.L.; Letsoalo, E.; Stevens, W.S.; Hardman, M.; Kityo, C.; Namayanja, G.; Nakatudde, L.; Nankya, I.; Kiconco, M.; Abwola, M.; Mugyenyi, P.; Ndembi, N.; Lyagoba, F.; Kaleebu 2011: HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study Lancet. Infectious Diseases 11(10): 750-759
Newman, H.; Breunig, L.; van Zyl, G.; Stich, A.; Preiser, W. 2014: A qualitative PCR minipool strategy to screen for virologic failure and antiretroviral drug resistance in South African patients on first-line antiretroviral therapy Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology 60(4): 387-391
Zhihua, Z.; Jianping, Y.; Miaomiao, S.; Kuisheng, C. 2014: Exploration for the multi-effect of cardamom in's resistance to multiple myeloma Pakistan Journal of Pharmaceutical Sciences 27(6 Suppl): 2001-2006
Kitamura, S.; Ishihara, Y.; Sasaki, K. 1977: Effect of vasoactive substances on the cyclic nucleotide contents of guinea-pig lung and tracheal tissues. 2. Effect of different doses of vasoactive substances Nihon Kyobu Shikkan Gakkai Zasshi 15(7): 391-398
Phillips, A.N.; Pillay, D.; Garnett, G.; Bennett, D.; Vitoria, M.; Cambiano, V.; Lundgren, J. 2011: Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings Aids 25(6): 843-850
Sun, D.; Liu, J.; Wang, Q.; Yang, W.; Yue, Y.; Guo, Z.; Yang, S.; Zhu, Q.; Wang, Z. 2015: Effect of treatment and HIV drug resistance of 81 cases of HCV/HIV co-infected individuals who had received AIDS second-line antiretroviral treatment in Henan province Zhonghua Liu Xing Bing Xue Za Zhi 36(6): 576-579
Ruane, P.J.; Daar, E.S. 2004: What's next? Treatment options when the first antiretroviral regimen fails virologically or is not tolerated, Part 1 Aids Reader 14(8): 421-6 431-2 434
Bendavid, E.; Wood, R.; Katzenstein, D.A.; Bayoumi, A.M.; Owens, D.K. 2009: Expanding antiretroviral options in resource-limited settings--a cost-effectiveness analysis Journal of Acquired Immune Deficiency Syndromes 52(1): 106-113
Danks, M.K.; Yalowich, J.C.; Beck, W.T. 1987: Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26) Cancer Research 47(5): 1297-1301
Binagwaho, A.; Pegurri, E.; Drobac, P.C.; Mugwaneza, P.; Stulac, S.N.; Wagner, C.M.; Karema, C.; Tsague, L. 2013: Prevention of mother-to-child transmission of HIV: cost-effectiveness of antiretroviral regimens and feeding options in Rwanda Plos one 8(2): E54180
Landolt, N.K.; Phanuphak, N.; Pinyakorn, S.; Lakhonphon, S.; Khongpetch, C.; Chaithongwongwatthana, S.; Ananworanich, J. 2012: Sexual life, options for contraception and intention for conception in HIV-positive people on successful antiretroviral therapy in Thailand Aids Care 24(7): 897-904
Vispo, E. 2007: SPRING: a new trial to evaluate tipranavir in heterogeneous treatment-experienced HIV populations Aids Reviews 9(2): 126-127
Bassetti, M.; Melica, G.; Di Biagio, A.; Rosso, R.; Gatti, G.; Bassetti, D. 2003: Gram-positive bacterial resistance: future treatment options Current Opinion in Investigational Drugs 4(8): 944-952